2024
Psilocybin and other Psychedelics
Kaye A, Kelmendi B, Rivera M, Pittenger C. Psilocybin and other Psychedelics. 2024 DOI: 10.1016/b978-0-323-95702-1.00178-0.Peer-Reviewed Original ResearchPsychedelic drugsSerotonin 5-HT2A receptorsHuman neuroimaging studiesAlcohol use disorderPatterns of activityTransdiagnostic efficacyDepressive disorderPsychedelic agentsClassic psychedelicsNeuroimaging studiesMode networkUse disorderPsychedelic propertiesPsychotherapeutic supportAssociation cortexPsilocybinPsychological effectsPsychedelicsDifferential effectsHealing contextControlled Substances ActDisordersPotential therapeutic useControlled studiesSerotonin
2023
Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders
Wang Z, Lin X, Luo X, Xiao J, Zhang Y, Xu J, Wang S, Zhao F, Wang H, Zheng H, Zhang W, Lin C, Tan Z, Cao L, Wang Z, Tan Y, Chen W, Cao Y, Guo X, Pittenger C, Luo X. Pleiotropic Association of CACNA1C Variants With Neuropsychiatric Disorders. Schizophrenia Bulletin 2023, 49: 1174-1184. PMID: 37306960, PMCID: PMC10483336, DOI: 10.1093/schbul/sbad073.Peer-Reviewed Original ResearchConceptsGray matter volumeBipolar disorderNeuropsychiatric disordersIntracranial volumeSingle nucleotide polymorphismsParkinson's diseaseCACNA1C variantsCACNA1C mRNARisk allelesAlcohol use disorderAverage cortical thicknessTotal intracranial volumeMultiple psychiatric disordersFalse discovery rate correctionDifferent neuropsychiatric disordersCortical surface areaBrain cohortCortical thicknessIndependent cohortPsychiatric disordersUse disordersMatter volumeSubcortical structuresSubstance dependenceDisease